Browsing by Subject "SARS-CoV"
Now showing items 21-40 of 128
-
COVID-19 in healthcare workers in three hospitals in the South of the Netherlands, March 2020
(2020-05-01)Background: Ten days after the first reported case of SARS-CoV-2 infection in the Netherlands, 3.9% of healthcare workers (HCWs) in nine hospitals located in the South of the Netherlands tested positive for SARS-CoV-2 RNA. ... -
COVID-19 in people living with human immunodeficiency virus: A case series of 33 patients
(2020-05-01)Data on people living with human immunodeficiency virus (PLWH) in the current SARS-CoV-2 pandemic is still scarce. This case series of 33 PLWH patients with COVID-19 reveals symptoms and outcome in this special population. ... -
COVID-19 progression is potentially driven by T cell immunopathogenesis
(2020-05-19)Background: The role of cellular immunity in pathogenesis of COVID-19 is unclear and conflicting data points to insufficient or pathogenic immunity as drivers of COVID-19 progression. Here we aimed to delineate the phenotype ... -
COVID-19 y uso de antimicrobianos: recomendaciones
(2020-11)Recomendaciones sobre el uso de antibióticos en pacientes con Diagnóstico de SARSCOV2. -
COVID-19: a promising cure for the global panic
(2020-04-04)The novel Coronavirus disease 2019 (COVID-19) is caused by SARS-CoV-2, which is the causative agent of a potentially fatal disease that is of great global public health concern. The outbreak of COVID-19 is wreaking havoc ... -
COVID-19: guía para la detección de SARS-CoV-2 en animales
(2020-10)El presente documento es una guía elaborada con la finalidad de establecer los lineamientos para la detección de SARS-CoV-2, causante de COVID-19, en animales. -
Covid2019 / SARSCoV2 coronavirus antivirals
(2020-04-20)Includes: Interferons, Nucleoside analogs, Protease inhibitors, Furin Convertase Cleavage inhibitors, Reverse transcriptase inhibitors, RNA Polymerase/Synthesis Inhibitors, Neuraminidase inhibitors, Angiotensin II receptor ... -
COVID‐19 treatment by repurposing drugs until the vaccine is in sight
(2020-03-29)Corona virus disease (COVID-19) has created pandemic in the world as declared by WHO on March 12, 2020. It is a viral disease caused by SARS-CoV 2 virus and has affected large populations in over 120 countries. There is ... -
Critérios técnicos para triagem clínica do coronavírus (SARS, MERS, SARS-CoV-2) nos candidatos à doação de órgãos e tecidos. Nota Técnica Nº 25/2020-CGSNT/DAET/SAES/MS
(2020)Critérios técnicos para triagem clínica do coronavírus (SARS, MERS, SARS-CoV-2) nos candidatos à doação de órgãos e tecidos e para manejo do paciente em lista de espera e do transplantado. -
Curbing the AI-induced enthusiasm in diagnosing COVID-19 on chest X-Rays: the present and the near-future
(2020-05-01)In the current context of COVID-19 pandemic, a rapid and accessible screening tool based on image processing of chest X-rays (CXRs) using machine learning (ML) approaches would be much needed. Initially, we intended to ... -
Decontamination and Reuse of Filtering Facepiece Respirators
(2020-04)Disposable filtering facepiece respirators (FFRs) are not approved for routine decontamination and reuse as standard of care. However, FFR decontamination and reuse may need to be considered as a crisis capacity strategy ... -
Developing Covid-19 Vaccines at Pandemic Speed
(2020-03-30)The need to rapidly develop a vaccine against SARS-CoV-2 comes at a time of explosion in basic scientific understanding, including in areas such as genomics and structural biology, that is supporting a new era in vaccine ... -
Dose prediction for repurposing nitazoxanide in SARS-CoV-2 treatment or chemoprophylaxis
(2020-05-06)Background: Severe acute respiratory syndrome coronavirus 2 (SARS−CoV−2) has been declared a global pandemic by the World Health Organisation and urgent treatment and prevention strategies are needed. Many clinical trials ... -
Early viral clearance and antibody kinetics of COVID-19 among asymptomatic carriers.
(2020-05-02)Background Asymptomatic carriers contribute to the spread of Coronavirus Disease 2019 (COVID-19), but their clinical characteristics, viral kinetics, and antibody responses remain unclear. Methods A total of 56 COVID-19 ... -
Epidemiological and clinical characteristics of the early phase of the COVID-19 epidemic in Brazil
(2020-04-29)Background: The first case of COVID-19 was detected in Brazil on February 25, 2020. We report the epidemiological, demographic, and clinical findings for confirmed COVID-19 cases during the first month of the epidemic in ... -
Establishment and Validation of a Pseudovirus Neutralization Assay for SARS-CoV-2
(2020-03-24)Pseudoviruses are useful virological tools because of their safety and versatility, especially for emerging and re-emerging viruses. Due to its high pathogenicity and infectivity and the lack of effective vaccines and ... -
FACT- Frankfurt adjusted COVID-19 testing- a novel method enables high-throughput SARS-CoV-2 screening without loss of sensitivity
(2020-05-01)Background: In the pandemic, testing for SARS-CoV-2 by RT-PCR in one of the pillars on which countermeasures are based. Factors limiting the output of laboratories interfere with the effectiveness of public health measures. ... -
False positives in reverse transcription PCR testing for SARS-CoV-2
(2020-05-20)Large-scale testing for SARS-CoV-2 by the reverse transcription polymerase chain reaction is a key part of the response to the COVID-19 pandemic, but little attention has been paid to the potential frequency and impacts ... -
Famotidine Use is Associated with Improved Clinical Outcomes in Hospitalized COVID-19 Patients: A Retrospective Cohort Study
(2020-05-08)Background: The SARS-CoV-2 pandemic has resulted in enormous morbidity and mortality worldwide, yet no medications to date are proven to improve clinical outcomes in hospitalized COVID-19 patients. Famotidine is commonly ...